Business Wire

NTT-COMMUNICATIONS

Share
NTT Communications: Digital Event Connects Tokyo and Kanazawa via World's Longest IOWN APN to Commemorate Hokuriku Shinkansen Line's Extension

NTT Communications Corporation (NTT Com) and the Hokuriku Regional Office of NTT DOCOMO, INC. (DOCOMO), together with the city of Kanazawa, celebrated the opening of a new section of the Hokuriku Shinkansen Line between Kanazawa and Tsuruga by holding digital events on March 16 under the theme of "Connection," a key component of NTT Group’s Innovative Optical and Wireless Network (IOWN) concept.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240325762257/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Scheme of live remote performance (Graphic: Business Wire)

The events included a live remote performance that seamlessly connected musicians in Kanazawa and Tokyo, a distance of about 1,000 kilometers, via the All-Photonics Network (APN). For the connection, NTT Com provided its APN Leased Line Plan powered by IOWN,2 which used the longest optical cable ever deployed in an IOWN demonstration and the first to be deployed in Japan's Hokuriku region.

The event brought together the Kanazawa Junior Jazz Orchestra JAZZ-21, consisting mainly of middle and high school students who have performed at the areas affected by the Great East Japan Earthquake and various major festivals around the world, and celebrated violinist Mayu Kijima, winner of numerous international competitions, including the 1st Shanghai Isaac Stern International Violin Competition in 2016, who performed with the Walner violin made by Antonio Stradivari 1699, which was on loan from the Munetsugu Collection.

Kanazawa City provided the demonstration environment and operated the venue in its area and NTT Com provided the APN transmission equipment and the venue in Tokyo. NTT Com and DOCOMO livestreamed the event on Kanazawa's metaverse platform using DOCOMO's 5G video transmission system, allowing viewers at home to enjoy the live event on PCs, smartphones and tablets via the browser-based virtual space platform DOOR.3 In addition, DOCOMO used its Hide Mode4 function to allow more people than normal to enter the virtual room. This was the first time in Japan that a metaverse space open to the public was used for a music event.

In another demonstration, smart lighting was used to allow spectators to digitally interact with Kanazawa's famous Tsuzumi-mon Gate to influence its illumination on the evening of March 16. Using 5G communication and IoT technology, spectators were able change the illumination by selecting from eight patterns via tablets placed near the gate. The demonstration, called “Connecting with Tsuzumi-mon Gate,” allowed people to make a special connection with the iconic site, including to take commemorative photos.

A third commemorative demonstration on March 16, called “Connecting with Other Locations,” allowed visitors to the Underground Plaza of the Motenashi Dome near Kanazawa Station to view and experience famous scenes along the Hokuriku Shinkansen line via a wide-angle virtual reality display without the use of goggles. During the demonstration, multiple people simultaneously enjoyed videos, 360-degree images and metaverse spaces, and even the experience of sitting in a Shinkansen driver's seat while traveling on the newly extended Hokuriku Shinkansen line.

DOCOMO group, under an agreement signed with the city of Kanazawa and West Japan Railway Company in 2019, is working to promote local attractions using 5G and other advanced technologies. Following the recent Noto Peninsula Earthquake on January 1, DOCOMO has strengthened its efforts to work with the people of the Hokuriku region to revitalize the region and support its recovery and reconstruction. Going forward, based on the lessons learned from the event to commemorate the Hokuriku Shinkansen Line's extension, NTT Com and DOCOMO are committed to providing new value to Kanazawa citizens and customers by incorporating new technologies, including the IOWN APN where possible, to promote the attractiveness of Kanazawa and contribute to the revitalization of the region.

1 Network infrastructure concept for creating an enriched society using advanced optical technologies, etc. IOWN® is a trademark of NTT Corporation. https://www.rd.ntt/e/iown/
2 NTT Com began offering APN communication services spanning prefectures from March 1 to meet customers' needs for advanced communication infrastructure.
3 DOCOMO's subsidiary NTT QONOQ INC. (https://www.nttqonoq.com/?lang=en) provides this service for holding events and displaying content in virtual spaces.
4 While 24 people is the normal recommended capacity of a virtual room, Hide Mode is a paid option that allows hundreds of people to enter, with certain limited capabilities. Please visit https://door.ntt/web/faq/index.html.

About NTT Communications
NTT Communications solves global technology challenges by helping enterprises utilize managed IT-infrastructure solutions to overcome complexity and risk in their IT environments. These solutions are backed by our worldwide infrastructure, including industry-leading, global tier-1 public and private networks reaching over 190 countries/regions, the world's most advanced data-center facilities (more than 500,000m2) and cutting-edge technologies for cloud, security and AI. As the core provider of the DOCOMO group's enterprise-business services and solutions, we create value by providing global-scale support for restructuring in industry and society, new workstyles and digital transformation in communities, leveraging 5G, IoT and other technologies under the "docomo business" brand. Together with NTT Ltd., NTT Data and NTT DOCOMO, we are the NTT Group.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com

About NTT DOCOMO
NTT DOCOMO, Japan’s leading mobile operator with over 89 million subscriptions, is one of the world’s foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240325762257/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release

Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release

Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through

Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release

Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r

Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release

Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye